source
- STAT+: Pharmalittle: We’re reading about an FDA gender rule change, its program for one-day inspections, and moreAn FDA proposal to remove references to “gender” from its regulations sparked concerns about unintended consequences on researchSTAT · 2mo ago↗ source
- Dr Gruenbaum on Where Alternative Options to BTK Inhibitors Stand in MCLLore Gruenbaum, PhD, discusses alternative treatments to BTK inhibitors like bispecific antibodies and CAR T-cell therapy in mantle cell lymphoma.onclive · 2mo ago↗ source
- The PYNNACLE Phase 2 trial assessing rezatapopt, a selective p53 reactivator, in patients with advanced or metastatic solid tumors harboring a TP53 Y220C mutation: Interim analysis of patients with ovarian cancerAlison Schram, MD, discusses interim PYNNACLE phase 2 data showing that single-agent rezatapopt produced clinically meaningful responses and a manageable safety profile in heavily pretreated patien…